More scientific evaluation is needed to develop and validate consensus recommendations to ensure that benefits will outweigh risks for consumers who use smartwatches in screening themselves for possible atrial fibrillation (AF), according to the authors of an article published in the journal Circulation.
Gregory Marcus (University of San Francisco, San Francisco, USA), was among the first to explore the potential of smartwatches to alert wearers about AF. The article is a response to a recent study in the same publication on the utility of Fitbit watches for detecting AF.
“Smartwatch detection of AF holds tremendous promise, but substantial work is needed to integrate this consumer-received information into optimised care of our individual patients and the well-being of the public,” Marcus writes.
Several years ago, Marcus and colleagues first investigated the Apple Watch as a potential tool to detect AF. Apple Watches and Fitbits both use optical photoplethysmography (PPG) sensors to track pulse. Using electrocardiogram (ECG) measurement to confirm the presence or absence of AF, Marcus and others found that smartwatch detection of irregular timing of heart beats could often point to cases of AF.
The most recent smartwatch models boast more refined algorithms to mathematically analyse PPG data and determine whether to alert the wearer about heartbeat irregularities. Some smartwatches in addition now incorporate single-lead electrocardiograph sensors that the user can activate.
In the Fitbit Heart Study, researchers reported that a little over 1% of 455,699 participants experienced one or more irregular heart-rhythm detections. About one-third of those who experienced irregular heartbeats and then wore a single-lead ECG monitor experienced an abnormal ECG reading suggestive of AF.
“But more studies are needed to better assess risks and benefits”, Marcus says.
“We might find that it makes sense for those at low-risk to opt out of alerts based on PPG data analysis,” he says. “Very little is known about AF health outcomes associated with smartwatch screening, and there are no rigorous studies to evaluate accuracy of AF detection using irregular heartbeat alerts that trigger immediate ECG recording”, Marcus notes.
The prevalence of AF increases with age. Prevalence of AF is unlikely to be much greater than 1% of adults in the USA, but about 5% of those age 60 and above are afflicted. Risk for AF is highest for individuals with pre-existing heart conditions. Besides age, additional risk factors include other chronic health conditions, among them potentially modifiable behaviours such as obesity and alcohol consumption.
Marcus notes that even a highly specific screening test can result in most positive results being falsely positive when disease incidence is low. Consider a hypothetical screening test that has a high accuracy, such as 95% “specificity” and “sensitivity.” This means 5% of true negatives test falsely positive. If true disease incidence in the screened population is just 1%, then about five people would be wrongly diagnosed for every person who was accurately diagnosed.
“False-positive results generate their own risks, including unnecessary worry and anxiety, unwarranted utilisation of medical resources, and sometimes treatment that may do more harm than good”, Marcus notes.
He suggests in his opinion piece that patients with already-confirmed AF might be among those to benefit most from smartwatch use: “Real-time AF detections can empower patients to identify triggers of their AF, to assess the effectiveness of various therapies, and to determine if vague or general symptoms are due to their arrhythmia or something else.”